StoneX raises MiniMed Group stock price target to $27 on results

MiniMed Group shares are riding strong momentum (+15% over the past week) after reporting Q1 revenue of $843M, up 17% YoY and above consensus ($827M) and StoneX’s estimate ($829M). StoneX lifted its price target to $27 (from $20) and kept a Buy rating, citing raised full-year organic revenue guidance and an maintained 16% adjusted EBITDA margin target; U.S. commercial execution drove 20% more new pump starts and 24% growth in new prescribers. Multiple analysts (UBS, BofA, BTIG, and Wells Fargo) also raised targets to $28/$26, reinforcing expectations for profitability in 2027 (EPS forecast $0.65).

Analysis

This is less about one beat and more about evidence that MMED’s operating model is starting to self-reinforce: higher prescriber adds should feed repeat starts, which in turn improves sales force productivity and lowers the cost of each incremental account. If that loop holds, the market can justify a re-rating from a “turnaround” multiple toward a growth-medtech multiple, especially since consensus still seems to be under-embedding the durability of the U.S. channel win.

The second-order read-through is negative for slower-moving pump and diabetes device peers like PODD and TNDM, not because they immediately lose share, but because MMED is signaling that physician adoption can still move materially with the right field execution and product availability. International sensor expansion is also important: once consumables penetrate more geographies, revenue quality improves and the installed base becomes stickier, which can support gross margin mix over the next 2-4 quarters if supply stays tight enough to limit discounting.

The main risk is that some of the acceleration is flattering and partially calendar-driven, so the stock can work in the next few weeks while fundamentals remain noisy. The real test is the next 1-2 quarters: if organic growth decelerates, prescriber growth normalizes, or EBITDA margin guidance slips, the rerating will stall quickly. A break back below the breakout zone in the low-$20s would suggest the market overestimated how much of this is durable share capture versus timing noise.

Key Decisions for Investors

• Buy MMED on pullbacks into the $22-23 area; upside toward $28-30 is plausible if the next print confirms that new-start momentum is repeatable, with a stop below the low-$21s if the breakout fails.
• Pair trade: long MMED / short TNDM or PODD for a 1-3 month relative-value expression on execution dispersion; thesis breaks if MMED growth normalizes or competitors show equalized start-rate trends.
• For investors already long, use strength to trim 20-30% and retain a core position into the next quarterly update; the stock has rerated quickly, so incremental upside now depends on guide quality more than the headline beat.
• If using options, prefer a call spread over outright calls: MMED Jan-2026 25/35 bull call spread captures further multiple expansion while limiting downside if analyst-target enthusiasm fades.